Erratum to Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Authors
Category Primary study
JournalThe Lancet Neurology
Year 2010
This article has no abstract
Epistemonikos ID: 04c6e99618104147aeecc0a6a044454d1476d9f0
First added on: Mar 31, 2022